The Latest Breaking News from Eli Lilly

The FDA has instituted a clinical hold on Foghorn Therapeutics Inc's (NASDAQ:FHTX) Phase 1 dose-escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).  The FDA initiated the partial clinical hold following the report of a recent death that occurred in a subject with potential differentiation syndrome.  Differentiation…

The Dow Jones Industrial Average sold off Thursday, as Cisco Systems stock plunged 12% on weak earnings results.

US crude oil futures traded lower, dropping around 1% on Thursday. Investors, meanwhile, focused on some notable insider trades.

The Dow Jones Industrial Average sold off Wednesday, as Target stock plunged 25% on weak earnings results.

Futures fell as Target dived early on a big profit miss. The stock market rally had a strong Tuesday. Broadcom looked actionable.

Dow Jones futures were higher Tuesday, as the rally attempt continues. Elon Musk suggested a Twitter deal could come at a lower price.

The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.

Eli Lilly's (NYSE:LLY) short percent of float has risen 6.85% since its last report. The company recently reported that it has 6.22 million shares sold short, which is 0.78% of all regular shares that are available for trading.

The Dow Jones Industrial Average dropped Monday, as the stock market paused after a two-day bounce off correction lows.

Eli Lilly and Albemarle lead five stocks that have shown resilience amid the sell-off and may be poised to lead the way forward.

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.